Julie R. Brahmer
Led CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer.
Thoracic oncologist whose nivolumab studies in squamous NSCLC and early PD-L1 antibody work established immunotherapy in lung cancer; long-term follow-up author of pembrolizumab first-line trials.
| Title | Journal | Year |
|---|---|---|
| Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer | New England Journal of Medicine | 2015 |
Patients with operable stage II-III lung cancer without EGFR or ALK alterations should have chemo-immunotherapy discussed before surgery rather than only afterwards. Three pre-operative cycles do not compromise the operation and improve cure rates. Whether to continue immunotherapy after surgery, as the perioperative trials do, and whether patients with pCR need any further treatment, remain open questions.
This study is why PD-1 inhibitors were developed across cancers rather than in melanoma alone: unexpected activity in lung cancer, historically thought immune-resistant, changed drug development priorities industry-wide. It also introduced PD-L1 immunohistochemistry as a candidate biomarker and pneumonitis as a signature toxicity. Within five years PD-1 blockade was approved in more than ten cancers.
Pages like this
not linked directly; found by shared links- PersonPatrick M. Forde
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Mesothelioma, Nivolumab.
- PersonSuzanne L. Topalian
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Nivolumab, PD-1.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Nivolumab, PD-1, Pembrolizumab, Non-small-cell lung cancer.
- PersonTasuku Honjo
Shares Nivolumab, PD-1, Pembrolizumab, Non-small-cell lung cancer.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Nivolumab, PD-1, Pembrolizumab.
- PersonDrew M. Pardoll
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, PD-1.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Nivolumab, PD-1, Pembrolizumab, Non-small-cell lung cancer.
- PersonDung T. Le
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, PD-1, Pembrolizumab.